In conclusion, the present findings indicate that KCNN4 could be considered a viable therapeutic target in PAAD, given that its inhibition has the potential to restore immune infiltration, counteract immune evasion, and enhance the effectiveness of immunotherapy. This evidence concerns the gene KCNN4 and pancreatic adenocarcinoma.